• 07-JUN-2016

Life Sciences sector creates value through digital innovation

PwC rated as an Advancing Vanguard Leader by ALM Intelligence

Digital is disrupting as much as it is building opportunities for life sciences (LS), perpetuating strategic challenges for operating models across pharmaceutical and medical device companies.

According to ALM Intelligence’s latest report ‘Digital Life Sciences Consulting 2016: Pharmaceutical and Medical Devices’, the adoption of digital approaches is permeating innovation, business strategies and enterprise improvements among large global and midsized pharma and medical device companies. 

As pharma and medical device manufacturers pursue new digital adoption in 2016, the life sciences sector is pursuing new ways to create value through innovation and functional improvements, including R&D, clinical trials, regulatory submissions and commercial activities. 

The report rates PwC as an Advancing Vanguard Leader in this area, naming it one of the leading providers of Digital LS Consulting globally. 

The report highlights that PwC is among the most capable advisors for digital LS consulting, earning very strong ratings and earning best-in-class among its competitive peers for digital LS strategy, LS innovation strategies, R&D clinical trial workflow strategies, and is very strong in digital LS analytics and digital LS technology.

It goes on to say that PwC’s LS sector clients are served through its pharma/life sciences practice, its Digital Services and recently launched DoubleJump HealthTM capabilities.  PwC’s investments in digital LS analytics capabilities reinforce the broad commitment by the firm to serve a wide array of integrated digital needs across the LS/HC ecosystem.

ALM Intelligence also states that PwC is one of the ‘Advancing’ firms.  PwC is advancing capabilities across its wide array of digital LS offerings, bringing together agency-minded design from its digital services, together with holistic LS research and planning from its Strategy& and pharma/life sciences practice for robust innovation-thru-design and strategy through execution approaches.

Doug Strang, Global and US Advisory Leader for Pharma/Life Sciences said:  “We are delighted that   
ALM Intelligence has rated PwC as the clear leader with an Advancing Vanguard position and the greatest depth and breadth of capabilities of any of our competitors.” 

Dan Garrett, US Leader for Health Industries Technology Consulting said: “PwC is helping pharmaceutical and life science organizations reimagine their business in the evolving New Health EconomyTM, by recreating end-to-end digital solutions from strategy and innovation through to execution.  Using digital approaches, we are helping to better connect these companies to their patients and consumers.”

*ALM Intelligence, formerly Kennedy Consulting Research & Advisory. 

Notes
1. For more information about how PwC's pharmaceuticals and life sciences practice helps pharmaceutical, biotech and medical device clients develop future focused business strategies and implement the time critical programmes and procedures essential to success within worldwide regulatory frameworks, visit https://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences.html
2. To find out more about how PwC has been evaluated by leading business, technology and industry analysts visit www.pwc.com/analystviews 
3. At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 157 countries with more than 208,000 people who are committed to delivering quality in assurance, advisory and tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com

PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

©2016 PwC. All rights reserved